12:00 AM
Sep 10, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

PUR118: Phase Ib data

Top-line data from a 4-part, dose-ranging Phase Ib trial in healthy volunteers and COPD patients showed that inhaled PUR118 was well tolerated. On exploratory endpoints, Pulmatrix said that PUR118 showed a "favorable" impact on biomarkers of airway inflammation and mucociliary clearance velocity. Data were...

Read the full 197 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >